Literature DB >> 20097022

New drug treatments for urinary incontinence.

Dudley Robinson1, Linda Cardozo.   

Abstract

Urinary incontinence remains a common and distressing condition affecting many women and is known to have a significant effect on quality of life (QoL). Whilst conservative and behavioural therapy are important in the management of women with both stress incontinence and overactive bladder (OAB) ultimately many may benefit from pharmacological therapy. Antimuscarinic drugs are the commonly used agents in the treatment of OAB although often compliance and persistence are affected by adverse effects. Consequently many newer agents remain under investigation. In addition duloxetine has recently been introduced for the management of women with stress incontinence and may offer an alternative to surgery in selected cases. The aim of this review is to provide an overview of the current and new developments in the management of women with urinary incontinence as well as reviewing the role of oestrogen therapy in relation to lower urinary tract dysfunction. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20097022     DOI: 10.1016/j.maturitas.2009.12.022

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  2 in total

1.  Izalpinin from fruits of Alpinia oxyphylla with antagonistic activity against the rat bladder contractility.

Authors:  Yuan Yuan; Yin-Feng Tan; Peng Xu; Hailong Li; Yong-Hui Li; Wen-Ya Chen; Jun-Qing Zhang; Feng Chen; Guo-Jun Huang
Journal:  Afr J Tradit Complement Altern Med       Date:  2014-06-04

2.  The prevalence and risk factors of overactive bladder symptoms and its relation to pelvic organ prolapse symptoms in a general female population.

Authors:  Tiny A de Boer; Marijke C P Slieker-ten Hove; Curt W Burger; Mark E Vierhout
Journal:  Int Urogynecol J       Date:  2010-11-23       Impact factor: 2.894

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.